3 0 4 VOLUME 45 | NUMBER 3 | MARCH 2013 Nature GeNetics l e t t e r s Craniosynostosis, the premature fusion of the cranial sutures, is a heterogeneous disorder with a prevalence of ~1 in 2,200 (refs. 1,2). A specific genetic etiology can be identified in ~21% of cases 3 , including mutations of TWIST1, which encodes a class II basic helix-loop-helix (bHLH) transcription factor, and causes Saethre-Chotzen syndrome, typically associated with coronal synostosis 4-6 . Using exome sequencing, we identified 38 heterozygous TCF12 mutations in 347 samples from unrelated individuals with craniosynostosis. The mutations predominantly occurred in individuals with coronal synostosis and accounted for 32% and 10% of subjects with bilateral and unilateral pathology, respectively. TCF12 encodes one of three class I E proteins that heterodimerize with class II bHLH proteins such as TWIST1. We show that TCF12 and TWIST1 act synergistically in a transactivation assay and that mice doubly heterozygous for loss-of-function mutations in Tcf12 and Twist1 have severe coronal synostosis. Hence, the dosage of TCF12-TWIST1 heterodimers is critical for normal coronal suture development.
Our exome sequencing approach focused on bilateral coronal craniosynostosis ( Fig. 1) because of previous evidence that this pathological group is loaded with cases of monogenic etiology 3 . We examined the variant lists from the whole-exome data 7 of seven unrelated individuals with bilateral coronal synostosis, negative for previously described mutations 8 , for genes showing nonsynonymous changes in two or more samples. Two samples had different heterozygous frameshift mutations in TCF12 (encoding transcription factor 12; also known as HEB, HTF4 and ALF1) [9] [10] [11] ; one (family 19) had a singlenucleotide deletion, and the other (family 30) had a four-nucleotide deletion (details in Supplementary Table 1 ). The mutations were confirmed by dideoxy sequencing of the original DNA samples (primary sequence results for all families are shown in Supplementary Fig. 1 ). In addition, a text search of the exome sequence data identified a new c.1468-20>A variant in TCF12 in a third sample (family 22), located 20 nucleotides upstream of the start of exon 17. This variant was predicted to generate a cryptic splice acceptor site that was confirmed experimentally (Supplementary Fig. 2a ). Thus, we had identified different heterozygous disruptive mutations of TCF12 in three of seven samples from individuals with bilateral coronal synostosis. We interrogated other exome or whole-genome sequencing projects on craniosynostosis that we were undertaking concurrently: this analysis identified additional TCF12 mutations in two siblings with bilateral coronal synostosis and their clinically unaffected mother (family 20, which we had erroneously analyzed assuming recessive inheritance) and in two unrelated individuals (from families 11 and 16) with clinical diagnoses of Saethre-Chotzen syndrome who did not have identified mutations in the TWIST1 gene 4-6 . Mutations in TCF12, encoding a basic helix-loop-helix partner of TWIST1, are a frequent cause of coronal craniosynostosis l e t t e r s
To confirm these findings and explore the clinical consequences of TCF12 mutations, we carried out dideoxy sequencing of TCF12 in individuals with different types of craniosynostosis in whom mutations had not previously been identified. In the initial panel of 287 unrelated samples, we identified 18 with pathogenic mutations in TCF12; all mutationpositive individuals had coronal synostosis. To replicate our findings, we sequenced an independent Dutch cohort of 50 samples with coronal synostosis and identified 14 additional mutations in TCF12. Overall, we observed a strong bias for mutations in TCF12 to occur in association with coronal synostosis ( Table 1) : 22 of 69 (32%) bilateral coronal and 14 of 141 (10%) unilateral coronal cases had mutations, but none of 93 cases with isolated metopic, sagittal or lambdoid synostosis had TCF12 mutations (P = 1 × 10 −6 , Fisher's exact test). The remaining two cases positive for TCF12 mutations had combinations of sagittal and either uni-or bilateral coronal synostosis, such that coronal synostosis was present in all 38 index subjects. In our extended Oxford birth cohort 3 with minimum 5-year follow-up (cases born in calendar years 1998-2006), we found TCF12 mutations in 4 of 402 subjects (1.0%; 95% confidence interval of 0.3-2.5%). Hence, mutations in TCF12 occur in a measurable fraction of craniosynostosis overall (Supplementary Fig. 3) .
The mutations identified in TCF12 comprise 14 nonsense, 15 frameshift, 7 splicing and 2 missense changes, suggesting a lossof-function mechanism (Fig. 2) . This is consistent with previous reports 12 of individuals with cytogenetically identified chromosome 15 deletions (predicted to include TCF12 at 15q21.3) in whom craniosynostosis was present, although no whole-exon deletions of TCF12 were detected in our subject panel using a multiplex ligation-dependent probe amplification (MLPA) assay. In cases with frameshift or splice-site mutations, analyses of mRNA extracted from various cell types showed lower expression of the mutant compared to the wild-type allele, consistent with nonsense-mediated mRNA decay ( Supplementary Fig. 2 and Supplementary . Using a transactivation assay with a reporter containing three E-boxes 15 , we found that the combination of native TCF12 and TWIST1 proteins had a synergistic effect on activation relative to the activity of either protein individually, but this effect was 65-76% lower in the presence of the TCF12 missense mutations encoding p.Leu624Pro or p.Gln638Glu alterations (Supplementary Fig. 4c ).
Of 36 families from which additional samples were available, the TCF12 mutation was shown to have arisen de novo in 14 ( Supplementary Fig. 1 5 for representative clinical photographs). There was no evidence to implicate somatic mosaicism in any of the non-penetrant cases, but preliminary analysis of haplotypes around TCF12 (which resides in a region of strong linkage disequilibrium) suggested that the allelic backgrounds of both non-mutant and mutant copies of TCF12 contribute to variability in the phenotype (data not shown). Of 14 mutationpositive relatives diagnosed with craniosynostosis involving specific sutures, 12 had coronal synostosis, and 2 had sagittal synostosis.
The clinical features associated with TCF12-related craniosynostosis are detailed (Supplementary Table 3) , and representative subjects with bilateral coronal synostosis (Fig. 1a) or unilateral coronal synostosis (Fig. 1b) are shown. In 15 probands (39%), a genetic cause was suspected because of a positive family history. In another seven probands (18%), clinical features (including dysmorphic appearance of the face and external ears and minor limb anomalies) were suggestive of Saethre-Chotzen syndrome, which had been excluded by negative TWIST1 mutation testing. The remaining subjects (16/38 = 42%) presented sporadically with apparently non-syndromic synostosis (Supplementary Table 1 Fig. 6 ), and no individuals positive for TCF12 mutations were documented to have an interval onset of raised intracranial pressure after their initial surgical procedure(s). Most individuals had normal developmental attainment, but ten (14%) had developmental delay or learning disability, which in two cases was associated with autism (clinical features are summarized in Supplementary 25 . Identical mutations identified in independent families are indicated (×2); note that mutations predicted to affect splicing are omitted from the protein schematic.
l e t t e r s
Tcf12 gene in the development of the immune system 13, 16 , but we found no history of infection susceptibility in individuals heterozygous for TCF12 mutations, and there was no detectable reduction in monocyte, natural killer (NK), T-cell or B-cell subsets or lower amounts of immunoglobulin in 11 mutation-positive individuals. Supporting our transactivation data ( Supplementary Fig. 4) , it was previously reported that TCF12 forms heterodimers with TWIST1 (ref. 17) and that TWIST1 haploinsufficiency causes Saethre-Chotzen syndrome [4] [5] [6] . Our observation that haploinsufficiency of TCF12 in humans leads specifically to coronal synostosis suggests that the total quantity of TCF12-TWIST1 heterodimers is a critical factor in coronal suture development. To test this hypothesis, we compared the phenotypes of the previously constructed individual heterozygous null mutant mice (EIIa-Cre; Tcf12 flox/+ and Twist1 +/− ) 16, 18, 19 to that of the compound heterozygotes (EIIa-Cre; Tcf12 flox/+ ; Twist1 +/− ). At 3 weeks of age, the EIIa-Cre; Tcf12 flox/+ animals (n = 14) had normal coronal sutures, indicating that the coronal suture is less sensitive to Tcf12 dosage in mice than in humans (Fig. 1c,d) ; Twist1 +/− mice (n = 4) showed variable coronal synostosis, as previously reported (Fig. 1e) 5, 20 . However, the EIIa-Cre; Tcf12 flox/+ ; Twist1 +/− compound heterozygotes (n = 6), which were born at a frequency close to the expected Mendelian ratio (25%), consistently showed severe coronal synostosis (Fig. 1f) .
The discovery that haploinsufficiency of TCF12 causes coronal synostosis in humans and that severe bilateral coronal synostosis occurs in mice with 50% of the wild-type dosage of both the Tcf12 and Twist1 genes highlights the key role of TCF12 acting with TWIST1, probably as a heterodimeric complex, in the normal development of the coronal sutures. The TCF12-TWIST1 heterodimer is likely to regulate specification of the boundary between the neural crest and cephalic mesoderm 20, 21 and/or inhibit osteogenic differentiation via actions on RUNX2 (ref. 22 ) and bone morphogenetic protein 23 or fibroblast growth factor receptor 17 signaling.
URLs. ANNOVAR, http://www.biobase-international.com/product/ annovar; GBrowse2, http://gmod.org/wiki/GBrowse; MRC-Holland, http://www.mrc-holland.com/; PolyPhen-2 http://genetics.bwh. harvard.edu/pph2; SAMtools, http://samtools.sourceforge.net.
METHodS
Methods and any associated references are available in the online version of the paper.
Accession codes. All cDNA numbering of TCF12 follows NCBI reference NM_207037.1, starting with A of the ATG initiation codon (+1). We used NM_207040.1 to design primers to the alternatively spliced first exon (9A). The genomic reference sequence is available under accession NC_000015.9. (MEC-2012-140 ). Written informed consent to obtain samples for genetics research was obtained from each child's parent or guardian. The clinical diagnosis of craniosynostosis was confirmed by CT scan, and evidence of associated syndromic features was sought by clinical examination. Venous blood was obtained for DNA and RNA extraction (collected into PAXgene Blood RNA tubes (Qiagen) for the latter procedure). Fibroblast cultures were established from skin biopsies obtained from the scalp incision at the time of surgical intervention. When clinically indicated, samples were tested for mutation hotspots in FGFR2, FGFR3 and TWIST1 (ref. 8) , and significant chromosome aneuploidy was investigated using aCGH; samples with identified mutations known to cause craniosynostosis were excluded. Seven samples from unrelated individuals with bilateral coronal synostosis were chosen for exome sequencing. These comprised five subjects who were clinically non-syndromic with negative family history, one subject who was clinically non-syndromic but reported to have two children with coronal synostosis and one subject who was the only individual in the family affected with craniosynostosis but who had short thumbs that were also present in several additional family members from the two previous generations.
Exome sequencing. We used an Agilent SureSelect Human All Exon Kit (v.2; 44 Mb) to capture exonic DNA from a library prepared from 3 µg of each proband's genomic DNA (extracted from whole blood). The enriched DNA was sequenced on an Illumina Genome Analyzer IIx platform with 51-bp paired-end reads. We generated between 3.98 and 4.56 Gb of sequence for each sample that, after mapping with Novoalign (Novocraft Technologies) to the hg19 genome and removal of artifacts using custom Perl scripts, resulted in an average coverage of exons of between 33-and 44-fold. Variants were called using SAMtools and annotated using ANNOVAR and PolyPhen-2. We removed all variants annotated in dbSNP132 and manually examined the gene lists for overlaps of two or more variants. Sequence data were visualized using GBrowse2.
Analysis of TCF12.
After the identification of candidate TCF12 mutations in the exome sequence, we confirmed and extended this analysis by direct sequencing of genomic PCR amplification products, MLPA and analysis of cDNA products. Details of the oligonucleotides and experimental conditions are provided in Supplementary Table 5 . Our initial screening panel mostly comprised samples recruited in Oxford 3 and other craniofacial units within the UK, and the replication panel comprised samples obtained in Rotterdam, The Netherlands. PCR amplification was performed in a volume of 20 µl, containing 15 mM Tris-HCl (pH 8.0), 50 mM KCl, 2.5 mM MgCl 2 , 100 µM each dNTP, 0.4 µM primers and 0.5 units of Amplitaq Gold polymerase (Applied Biosystems), with or without 10% DMSO, as indicated. Cycling conditions consisted of an 8-min denaturation step at 94 °C, followed by 35 cycles of 94 °C for 30 s, annealing at 65 °C (unless otherwise indicated in Supplementary  Table 5) for 30 s and extension at 72 °C for 30 s, with a final extension at 72 °C for 10 min. Amplification products were sequenced using the BigDye Terminator v3.1 cycle sequencer system (Applied Biosystems). All mutations were reconfirmed, either by restriction digestion of 5 µl of PCR product or by repeat dideoxy sequencing of an independent PCR product. In addition to the mutations listed in Supplementary Table 1, we identified two previously unreported variants in single individuals that are currently of uncertain pathogenic significance, c.630T>G (p.Ser210Arg) and c.982A>G (p.Asn328Asp).
Copy-number variation was analyzed by MLPA performed using synthetic oligonucleotide probes designed to TCF12 according to protocols available from MRC-Holland. Fragments were analyzed by capillary electrophoresis using an ABI 3130 containing POP-7 polymer. Peaks were visualized using Gene Mapper v3.7 (Applied Biosystems). Normal MLPA results were obtained in 226 craniosynostosis samples negative for intragenic TCF12 mutations. For studies of splicing and mRNA stability, RNA was extracted from whole blood and fibroblasts using TRIzol reagent. cDNA was synthesized using the Fermentas RevertAid First-Strand Synthesis kit with random hexamer primers according to the manufacturer's instructions. The microsatellites used to confirm sample relationships were D3S1311, D4S403, D5S2027, D6S1610, D7S519, D9S158, D10S548, D11S898, D13S1265, D14S280, D16S415 and D18S474.
Immune function tests. Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood by density gradient centrifugation in cell separation tubes (Sigma), washed three times in sterile PBS and rested overnight in RPMI 1640 medium supplemented with 10% FCS, 1% l-glutamine, 1% penicillinstreptomycin solution and 50 µM β-mercaptoethanol (all from Sigma) and 1% HEPES buffer (GibcoBRL). Monocytes, NK cells and naive, effector and memory T-and B-cell subsets were enumerated by flow cytometry of PBMCs stained with human-specific antibodies against CD3, CD4, CD19, CD14, CCR7, CD45RO, CD62L, CD16, CD56, CD25, IgD, IgM, CD10 and CD27 (Supplementary Table 6 ). Total IgM, IgA and IgG antibody titers were measured by ELISA.
Transactivation analysis of missense mutations. We obtained a full-length TCF12 cDNA clone (pCMV6-XL5, encoding HEBβ) from OriGene and synthesized the TWIST1 clone (pCMV-Twist) in house. The pCaSpeR-Tinman::lacZ (pTinE1/E2/E3) construct (containing three Tinman E-boxes comprising two 5′-CATGTG-3′ and one 5′-CATATG-3′) was used as a bHLH proteinresponsive reporter, and placZ (containing no E-boxes) was used as a control (both constructs were gifts from E.-M. Füchtbauer) 15 . PCR mutagenesis was used to introduce the c.1871T>C and c.1912 C>G mutations into the TCF12 cDNA using the primers indicated in Supplementary Table 5 ; mutated cDNAs were fully verified by sequencing.
The HT1080 human cell line was cultured in high-glucose DMEM (Invitrogen) supplemented with 10% FCS. Cells were transfected in triplicate with 1 µg of reporter plasmid, 1 µg each of TWIST1 and TCF12 constructs or the corresponding empty expression vectors using Promega FuGENE 6 transfection reagent according to the manufacturer's protocols. Transfections were carried out when cells were ~50% confluent in 6-well plates. Cells were harvested after 48 h, and β-galactosidase assays were performed in triplicate on 5 µl of cellular extract using the Galacto-Star system (Applied Biosystems). The missense mutations were modeled in Protein Workshop onto the structure of mouse E47/NeuroD1 (Protein Data Bank (PDB) accession 2QL2) 26 .
Analysis of mouse mutants. The mouse mutants analyzed were Tcf12 flox (obtained on a mixed C57BL/6/129 background as a gift of Y. Zhuang) 16 , EIIa-Cre (purchased from The Jackson Laboratory (B6.FVB-Tg(EIIa-cre) C5379Lmgd/J) 18 and Twist1 (C57BL/6 background) 19 . The EIIa-Cre transgene was detected using primers Cre-F and Cre-R (Supplementary Table 5) ; Tcf12 flox and Twist1 were genotyped as described 16, 19 . Heads of P21 mice were skinned and stained for mineralized bone with Alizarin Red S (80 mg/l in 1% KOH) for 3 d. Skulls were then cleared and stored in 100% glycerol. P21 mouse skulls were scanned using a µCT system (SCANCO µCT 50, Scanco Medical AG) and analyzed using Amira software (Visage Imaging). All scans were conducted at an energy setting of 70 kVp, current intensity of 200 µA, integration time of 500 ms/projection, 0.24 degree rotational step (DRS) and a field of view (FOV) of 15.1 mm. Scans were performed at a 10-µm isotropic resolution. In the version of this article initially published, numbering and spacing for the exon structure of TCF12 in Figure 2a was incorrect. The error has been corrected in the HTML and PDF versions of the article.
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